GC
VIR icon

Guggenheim Capital’s Vir Biotechnology VIR Stock Holding History

Guggenheim Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-70,606
Closed -$662K – 1958
2023
Q3 		$662K Buy
70,606
+7,455
+12% +$106K 0.01% 1291
2023
Q2 		$1.55M Buy
63,151
+10,777
+21% +$271K 0.01% 967
2023
Q1 		$1.22M Buy
52,374
+34,592
+195% +$885K 0.01% 1071
2022
Q4 		$450K Buy
17,782
+3,568
+25% +$87.5K ﹤0.01% 1528
2022
Q3 		$274K Sell
14,214
-15,873
-53% -$404K ﹤0.01% 1691
2022
Q2 		$766K Buy
+30,087
New +$702K 0.01% 1356

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Guggenheim Capital's VIR Position: Q4 2023 in Review

Guggenheim Capital sold out of Vir Biotechnology (VIR) in Q4 2023, closing a stake of 70,606 shares — an estimated $662K sold.

Guggenheim Capital first reported a position in VIR in Q2 2022 and held it in 6 quarters. The position peaked at $1.55M in Q2 2023. 206 funds tracked by Wall St. Rank hold VIR as of Q4 2023.

  • Guggenheim Capital reported no remaining Vir Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Guggenheim Capital sold 70,606 Vir Biotechnology shares in Q4 2023, an estimated $662K.
  • Guggenheim Capital first reported a position in Vir Biotechnology in Q2 2022 and held it in 6 quarters.
  • Guggenheim Capital's Vir Biotechnology position peaked at $1.55M in Q2 2023.
  • 206 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2023.

Based on Guggenheim Capital's 13F filing for Q4 2023, filed 14 Feb 2024.